Team Stockkey

Canadian

Microsoft Is a Buy on Any 10% Dip — But This Canadian Tech Stock Offers Even More Upside

The Magnificent Seven stocks have earned their reputation for consistent growth and resilience. Among them, Microsoft (NASDAQ:MSFT) stands out as a particularly compelling buy — especially if the stock experiences a 10% pullback. While it may not be the fastest mover of the group, Microsoft’s stability, scale, and future growth potential make it a cornerstone…

Read More
Hand inserting a coin into a blue piggy bank for savings and money management.

Why Capital Power Is a Top Dividend Growth Stock to Buy Now

A dividend-focused investment strategy typically revolves around stable, income-generating companies. But while consistent payouts are important, dividend growth is often an even better indicator of long-term financial health and shareholder value. Dividend growers — companies that increase their payouts year after year — tend to be well-managed, financially sound, and positioned for sustainable growth. The…

Read More
health

This Penny Stock Advances Clinical Pipeline and Solidifies Financial Position in Q2 2025

About AbCellera AbCellera is a clinical-stage biotechnology company that leverages advanced technologies to discover and develop antibody-based therapeutics. Founded with the vision of transforming the way antibody drugs are discovered, AbCellera integrates AI-powered drug discovery platforms with deep expertise in immunology and protein engineering. Clinical Development Milestones Achieved AbCellera (Nasdaq: ABCL) announced significant progress in…

Read More
A person trades stocks on a smartphone with a laptop, coffee cup, calculator, and documents in view.

Solid Q2 2025 Performance with Continued Shareholder Returns Makes This Dividend Stock a Buy

During the second quarter of 2025, South Bow Corp (TSX:SOBO) delivered stable financial results, underpinned by the strong commercial performance of South Bow. Total revenue for the quarter reached $524 million, with net income of $96 million, or $0.46 per share. While normalized EBITDA¹ declined 6% year-over-year to $250 million—primarily due to expected lower contributions…

Read More
×